Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221631 | 0.84 | GPR3 (0.45) | GPR3GAAALDH1A1POLBTHRB | |
| SCHEMBL29427162 | 0.84 | GPR3 (0.45) | GPR3GAAALDH1A1POLBTHRB | |
| SCHEMBL30867033 | 0.81 | GPR3 (0.49) | GPR3GAAFFAR4KIF11MAPK1 | |
| SCHEMBL171112 | 0.81 | GPR3 (0.49) | GPR3GAAFFAR4KIF11MAPK1 | |
| SCHEMBL12180463 | 0.78 | GPR3 (0.44) | GPR3FFAR4CRHR1SCN5AGRIN2B | |
| SCHEMBL5158453 | 0.78 | ALDH1A1 (0.46) | GPR3GAAALDH1A1POLBTHRB | |
| SCHEMBL15718212 | 0.78 | GPR3 (0.46) | GPR3GAAALDH1A1POLBTHRB | |
| SCHEMBL30018924 | 0.78 | GPR3 (0.46) | GPR3GAAALDH1A1POLBTHRB | |
| SCHEMBL900910 | 0.78 | PDE2A (0.47) | GPR3GAAFFAR4KIF11MAPK1 | |
| SCHEMBL20650170 | 0.78 | GPR3 (0.46) | GPR3GAAFFAR4KIF11MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-101263131-B | Urea glucokinase activators | TRANSTECH PHARMA INC | 2013-04-24 | — | — | CN | disclosed |
| CN-101065363-B | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV | 2012-05-02 | — | — | CN | disclosed |
| CN-101133036-B | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2010-10-13 | — | — | CN | disclosed |
| CN-101263131-A | Urea glucokinase activators | NOVO NORDISK AS (US) | 2008-09-10 | — | — | CN | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| CN-101133036-A | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | CN | disclosed |
| CN-101065363-A | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-31 | — | — | CN | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | GPR3 566/4885GAA 1625/4885ALDH1A1 364/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | GPR3 619/4885GAA 1563/4885ALDH1A1 340/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | GPR3 610/4885GAA 1736/4885ALDH1A1 362/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | GPR3 3446/4885GAA 500/4885ALDH1A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.